drugset

drugset / Trial / NCT06171074

Study of CM310 in Subjects With Seasonal Allergic Rhinitis

NCT06171074 ↗

Phase 2 Unknown 100 enrolled Keymed Biosciences Co.Ltd

NaSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, single arm phase II clinical study mainly evaluating the efficacy of CM310 in patients with seasonal allergic rhinitis.

Timeline

Start: 2024-03-30
Primary completion: 2025-03-30
Completion: 2025-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM310	Monoclonal antibody	—	Subcutaneous

Indications